New Leaf Venture Partners appeared to be the VC, which was created in 2005. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the New York.
The high activity for fund was in 2012. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. When the investment is from New Leaf Venture Partners the average startup value is more than 1 billion dollars. Comparing to the other companies, this New Leaf Venture Partners performs on 3 percentage points less the average number of lead investments. The top amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 7-12 deals per year.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the New Leaf Venture Partners, startups are often financed by Spray Venture Partners, InterWest Partners, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Aberdare Ventures, Clarus Ventures. In the next rounds fund is usually obtained by SV Health Investors, Aberdare Ventures, Three Arch Partners.
This organization was formed by James Niedel, Jeani Delagardelle, Philippe Chambon, Ronald M. Hunt, Vijay Lathi. The overall number of key employees were 2.
Among the most successful fund investment fields, there are Genetics, Health Diagnostics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Synageva BioPharma, Intarcia Therapeutics, Relypsa The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Qlaris Bio | $24M | 30 Apr 2024 | Cambridge, Massachusetts, United States | ||
Flosonics | $20M | 19 Mar 2024 | Greater Sudbury, Ontario, Canada | ||
Star Therapeutics | $90M | 05 Sep 2023 | South San Francisco, California, United States | ||
Arine | $29M | 17 Aug 2022 | San Francisco, California, United States | ||
Electra Therapeutics | $84M | 16 Feb 2022 | San Francisco, California, United States | ||
Asimily | $10M | 02 Nov 2021 | Sunnyvale, California, United States | ||
DiCE Molecules | $60M | 24 Aug 2021 | California, United States | ||
Cleerly | $43M | 21 Jun 2021 | New York, New York, United States | ||
BrightInsight | $101M | 30 Mar 2021 | San Jose, California, United States |
– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.
– Cleerly, a NYC-based company creating a new standard of care for heart disease, launched with $43m in Series B funding.
– The round was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors.
– The company intends to use the funds to scale its commercial reach, expand operational capabilities and strategic partnerships, and continue to grow its focus on research and development.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Qlaris Bio | $24M | 30 Apr 2024 | Cambridge, Massachusetts, United States | ||
Flosonics | $20M | 19 Mar 2024 | Greater Sudbury, Ontario, Canada | ||
Star Therapeutics | $90M | 05 Sep 2023 | South San Francisco, California, United States | ||
Arine | $29M | 17 Aug 2022 | San Francisco, California, United States | ||
Electra Therapeutics | $84M | 16 Feb 2022 | San Francisco, California, United States | ||
Asimily | $10M | 02 Nov 2021 | Sunnyvale, California, United States | ||
DiCE Molecules | $60M | 24 Aug 2021 | California, United States | ||
Cleerly | $43M | 21 Jun 2021 | New York, New York, United States | ||
BrightInsight | $101M | 30 Mar 2021 | San Jose, California, United States |
